Drug Trial Radar · NCT00504881
Brivaracetam as add-on Treatment in Adolescents and Adults Suffering From Epilepsy
Last checked: Nov 20, 2026Latest source record: Apr 3, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
480
Actual
Start
Oct 2007
Primary completion
Nov 2008
Study completion Dec 2008
Sponsor
- Lead sponsor
- UCB Pharma SAUCB
- Sponsor type
- Industry
- First posted
- Jul 20, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 16 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will compare the safety and efficacy of Brivaracetam at flexible dose with Placebo in subjects suffering from Epilepsy.
Conditions
- Epilepsy
Interventions
PlaceboDrug
Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 16-week Treatment Period
BrivaracetamDrug
Daily oral dose of two equal intakes, morning and evening, Brivaracetam 20 mg/day or Brivaracetam 50 mg/day or Brivaracetam 100 mg/day or Brivaracetam 150 mg/day, in a double-blinded way for the 16-week Treatment Period
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Subjects With at Least One Adverse Event During the 16-week Treatment PeriodTime frame: Week 2 to the end of the Treatment Period (Week 16)
- Partial Onset Seizure (Type I) Frequency Per Week Over the 16-week Treatment PeriodTime frame: Baseline (Week 0) to the end of the Treatment Period (Week 16)
Locations
61 sites in 15 countries. Site status is shown where the registry gives one.
Site not named
Graz, Austria
Site not named
Innsbrick, Austria
Site not named
Linz, Austria
Site not named
Vienna, Austria
Site not named
Bruges, Belgium
Site not named
Godinne, Belgium
Site not named
Leuven, Belgium
Site not named
Montignies-sur-Sambre, Belgium
Site not named
Beroun, Czechia
Site not named
Brno, Czechia
Site not named
Ostrava Trebovice, Czechia
Site not named
Prague, Czechia
Site not named
Zlín, Czechia
Site not named
Berlin, Germany
Site not named
Bernau, Germany
Site not named
Bielefeld, Germany
Site not named
Erlangen, Germany
Site not named
Göttingen, Germany
Site not named
Jena, Germany
Site not named
München, Germany
Site not named
Hong Kong, Hong Kong
Site not named
Bangalore, India
Site not named
Hyderabad, India
Site not named
Mumbai, India
Site not named
New Delhi, India
Site not named
Pune Maharashtra, India
Site not named
Tirupati, India
Site not named
Bari, Italy
Site not named
Milan, Italy
Site not named
Pavia, Italy
Site not named
Roma, Italy
Site not named
Siena, Italy
Site not named
Bergen, Norway
Site not named
Fredrikstad, Norway
Site not named
Oslo, Norway
Site not named
Sandvika, Norway
Site not named
Trondheim, Norway
Site not named
Kazan', Russia
Site not named
Moscow, Russia
Site not named
Saint Petersburg, Russia
Showing 40 of 61 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.